IMARC Group’s report titled “Veterinary Vaccines Market Report by Vaccine Type (Livestock Vaccines, Companion Animal Vaccines), Technology (Attenuated Live Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Others), Route of Administration (Subcutaneous, Intramuscular, Intranasal), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies and Drug Stores, and Others), and Region 2024-2032”. The global veterinary vaccines market size reached US$ 13.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 28.0 Billion by 2032, exhibiting a growth rate (CAGR) of 8.12% during 2024-2032.
Grab a sample PDF of this report: https://www.imarcgroup.com/veterinary-vaccines-market/requestsample
Factors Affecting the Growth of Veterinary Vaccines Industry:
- Increasing Pet Ownership and Companion Animal Population:
The rise in pet ownership worldwide has significantly contributed to the growth of the veterinary vaccines market. As more individuals welcome pets into their families, the demand for preventive healthcare measures, including vaccinations, has intensified. This trend is particularly noticeable in developed regions such as North America and Europe, where pet ownership rates are notably high. Moreover, emerging economies, such as China and India are witnessing a rise in disposable income levels, leading to increased spending on pet healthcare. The burgeoning companion animal population further propels the demand for veterinary vaccines. With more pets in households, the risk of infectious diseases spreading among animals also escalates. Veterinary vaccines play a pivotal role in preventing various infectious diseases such as rabies, canine distemper, feline leukemia, and parvovirus, thus safeguarding the health and well-being of pets. Additionally, the growing awareness among pet owners regarding the importance of regular vaccination schedules to protect their furry companions from preventable illnesses has spurred the adoption of veterinary vaccines.
- Significant Technological Advancements and Product Innovations:
Technological advancements and product innovations play a pivotal role in driving growth within the veterinary vaccines market. The field of veterinary medicine has witnessed remarkable progress in recent years, fueled by advances in biotechnology, genomics, and immunology. These technological breakthroughs have revolutionized vaccine development and production processes, leading to the creation of safer, more efficacious, and genetically engineered vaccines. One significant advancement in vaccine technology is the development of recombinant DNA vaccines. These vaccines are designed to trigger a targeted immune response by introducing genetic material from pathogens into host cells, stimulating the production of protective antigens. Recombinant DNA vaccines offer several advantages over traditional vaccine approaches, including improved safety profiles, enhanced immunogenicity, and the ability to induce broader and longer-lasting immune responses.
- Increasing Incidence of Zoonotic Diseases:
The rising incidence of zoonotic diseases is a significant driver propelling the growth of the veterinary vaccines market. Zoonotic diseases are infectious diseases that can be transmitted between animals and humans, posing significant public health threats. With increasing urbanization, changes in land use, and greater proximity between humans and animals, the risk of zoonotic disease transmission has escalated globally. One notable instance of a zoonotic disease is rabies, a deadly viral infection that affects both animals and humans. Rabies is primarily transmitted through the bite of an infected animal, such as dogs, bats, or wildlife. Vaccination plays a crucial role in rabies prevention, with mass vaccination campaigns targeting both domestic and wild animal populations being instrumental in controlling the spread of the disease. The demand for veterinary rabies vaccines is particularly high in regions where rabies remains endemic, driving market growth.
Explore full report with table of contents: https://www.imarcgroup.com/veterinary-vaccines-market
Leading Companies Operating in the Global Veterinary Vaccines Industry:
- Boehringer Ingelheim International GmbH
- Ceva Santé Animale
- Elanco Animal Health Incorporated
- Hester Biosciences Limited
- HIPRA, Indian Immunologicals Limited
- Merck & Co. Inc.
- Neogen Corporation
- Phibro Animal Health Corporation
- Virbac SA and Zoetis Inc.
Veterinary Vaccines Market Report Segmentation:
By Vaccine Type:
- Livestock Vaccines
- Bovine Vaccines
- Poultry Vaccines
- Porcine Vaccines
- Others
- Companion Animal Vaccines
- Canine Vaccines
- Feline Vaccines
- Equine Vaccines
Livestock vaccines hold maximum number of shares due to the extensive global demand for vaccines to prevent infectious diseases in livestock populations, which are vital for ensuring food security and sustaining agricultural productivity.
By Technology:
- Attenuated Live Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Others
Attenuated live vaccines dominate the market due to their ability to closely mimic natural infections, eliciting robust and long-lasting immune responses against a broad spectrum of pathogens in both veterinary and human medicine.
By Route of Administration:
- Subcutaneous
- Intramuscular
- Intranasal
Subcutaneous represents the largest segment due to its ease of administration, high patient acceptance, and ability to provide sustained release of vaccine antigens.
By Distribution Channel:
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies and Drug Stores
- Others
Veterinary clinics dominate the market due to their role as primary points of contact for pet owners seeking comprehensive veterinary care, including vaccination services, for their animals.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America’s dominance in the veterinary vaccines market is attributed to factors such as high pet ownership rates, stringent regulatory standards, advanced healthcare infrastructure, and robust research and development activities in the veterinary vaccines sector.
Global Veterinary Vaccines Market Trends:
Government initiatives and policies aimed at promoting animal health and welfare play a significant role in driving the veterinary vaccines market. Many governments worldwide implement vaccination programs targeting livestock populations to control and prevent the spread of infectious diseases, enhance food safety, and support agricultural productivity. These programs often involve subsidies or incentives to encourage farmers and livestock producers to vaccinate their animals regularly, thereby boosting the demand for veterinary vaccines. Additionally, stringent regulations mandating the vaccination of certain animals, such as pets, working animals, and livestock, further drive market growth by ensuring compliance with preventive healthcare measures. Government-funded research grants and collaborations with pharmaceutical companies also foster innovation in vaccine development, leading to the introduction of new and improved veterinary vaccines to address emerging disease threats and public health concerns.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145 | United Kingdom: +44–753–713–2163
